Addition of tumor multiplicity improves the prognostic performance of the hepatoma arterial-embolization prognostic score.

Park, Yehyun; Kim, Seung Up; Kim, Beom Kyung; Park, Jun Yong; Kim, Do Young; Ahn, Sang Hoon; Park, Yong Eun; Park, Ji Hye; Lee, Yong Il; Yun, Hae Ryong; Han, Kwang-Hyub
Liver international : official journal of the International Association for the Study of the Liver
2016Jan ; 36 ( 1 ) :100-7.
ÀúÀÚ »ó¼¼Á¤º¸
Park, Yehyun -
Kim, Seung Up -
Kim, Beom Kyung -
Park, Jun Yong -
Kim, Do Young -
Ahn, Sang Hoon -
Park, Yong Eun -
Park, Ji Hye -
Lee, Yong Il -
Yun, Hae Ryong -
Han, Kwang-Hyub -
ABSTRACT
BACKGROUND & AIMS: The hepatoma arterial-embolization prognostic (HAP) score predicts survival outcome in patients with hepatocellular carcinoma (HCC) treated with trans-arterial chemoembolization (TACE). We validated the HAP score in Korean subjects with HCC and investigated whether its prognostic performance is improved with additional parameters.

METHODS: A total of 280 patients with HCC treated with TACE between 2003 and 2009 were included. Validation and modification of HAP score were performed based on multivariate Cox regression models.

RESULTS: The median age of the study population (211 men, 69 women) was 60 years. Viral etiology of HCC accounted for 80.4% (n = 181 for hepatitis B, 44 for hepatitis C). The median overall survival (OS) was 40.5 months. On multivariate analysis, together with the original components of the HAP score (serum albumin <3.6 g/dl, total bilirubin >0.9 mg/dl, alpha-foetoprotein >400 ng/ml, and tumor size >7 cm), tumor number ?? was selected as an independent unfavorable prognostic factor for OS (hazard ratio 2.3; P < 0.001). Accordingly, a modified HAP-II (mHAP-II) score was established by adding tumor number ??. Although both HAP and mHAP-II scores discriminated the four different risk groups (log-rank test, all P < 0.001), the mHAP-II score performed significantly better than the HAP score, as per the areas under receiver-operating curves predicting OS at 3 years (0.717 vs. 0.658) and 5 years (0.728 vs. 0.645), respectively (all P < 0.05).

CONCLUSIONS: Although the HAP score predicted OS for Korean subjects with HCC undergoing TACE, the addition of tumor number significantly improved the prognostic performance. The mHAP-II score can be used for accurate prognostication and selection of optimal candidates for TACE. CI - ??2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
keyword
hepatocellular carcinoma; model; overall survival; prediction; prognosis; trans-arterial chemoembolization
¸µÅ©

ÁÖÁ¦ÄÚµå
ÁÖÁ¦¸í(Target field)
¿¬±¸´ë»ó(Population)
¿¬±¸Âü¿©(Sample size)
´ë»ó¼ºº°(Gender)
Áúº´Æ¯¼º(Condition Category)
¿¬±¸È¯°æ(Setting)
¿¬±¸¼³°è(Study Design)
¿¬±¸±â°£(Period)
ÁßÀç¹æ¹ý(Intervention Type)
ÁßÀç¸íĪ(Intervention Name)
Å°¿öµå(Keyword)
À¯È¿¼º°á°ú(Recomendation)
The HAP score accurately predicted OS for Korean subjects with HCC undergoing TACE, and the addition of tumor number (for the mHAP-II score) significantly improved the prognostic performance.
¿¬±¸ºñÁö¿ø(Fund Source)
±Ù°Å¼öÁØÆò°¡(Evidence Hierarchy)
ÃâÆdz⵵(Year)
Âü¿©ÀúÀÚ¼ö(Authors)
´ëÇ¥ÀúÀÚ
DOI
https://doi.org/10.1111/liv.12878
KCDÄÚµå
ICD 03
°Ç°­º¸ÇèÄÚµå